ADA and metabolic dysfunction-associated steatotic liver disease: This is particularly intriguing because adenosine deaminase (ADA), the enzyme that catalyzes the conversion of adenosine to inosine, is known to be more active in type 2 diabetic patients (Kurtul et al., 2004) and is associated with liver fibrosis in NAFLD (Jiang et al., 2018).